Advagene Biopharma Co., Ltd. (TPEX:6709)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
31.00
-2.00 (-6.06%)
Mar 4, 2026, 1:47 PM CST
Market Cap1.96B +60.2%
Revenue (ttm)n/a
Net Income-71.10M
EPS-1.23
Shares Out59.38M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume97,959
Average Volume163,316
Open32.00
Previous Close33.00
Day's Range30.90 - 33.10
52-Week Range15.75 - 41.00
Beta0.78
RSI55.76
Earnings DateMar 20, 2026

About Advagene Biopharma

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. It engages in the development of nasal spray influenza vaccine; respiratory allergy treatment vaccine, including rhinitis and asthma; COVID-19 immunotherapy; and other vaccines. The company was founded in 2006 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 12
Stock Exchange Taipei Exchange
Ticker Symbol 6709
Full Company Profile

Financial Performance

Financial Statements